Merit Medical Q1 Adjusted EPS Beats Estimates, Revenue Up 7% on Therapeutic & Foundational Growth; Outlook Raised
MMSI is trading near its 52-week low of $63.78 (6.9% above the low).
Summary
Merit Medical Systems reported strong first-quarter results, with adjusted EPS of $0.94 significantly beating the analyst consensus of $0.83. Revenue increased 7% year-over-year, fueled by robust growth in both its Therapeutic (up 10%) and Foundational (up 6%) product categories. The company also announced the divestiture of its DualCap product line and the acquisition of View Point Medical to expand its oncology offerings. This positive performance builds on the strong financial results reported in the prior year's 10-K. The company provided an optimistic 2026 outlook, projecting revenue growth of 6%-8% and non-GAAP EPS growth of 5%-8%, which should be viewed favorably by investors. Traders will be watching the integration of the new acquisition and continued organic growth trends.
At the time of this announcement, MMSI was trading at $68.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $63.78 to $100.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.